Theranos Continues to Confront Thunderheads Regarding Accuracy of Its Testing Platform

摘要

Whether or not in its uncertain future it manages to survive or even thrive, Theranos will at least receive credit for never being boring. The Theranos saga has just entered its most critical state, as the Centers for Medicare & Medicaid Services (CMS) recommended the company's CLIA certification be revoked for its California lab only days after its scathing inspection report was made public. Meanwhile, a group of researchers from one of the most prestigious teaching hospitals in the nation questioned the validity of Theranos' testing platform. Theranos responded by deflecting the former while attacking the latter, all the while appointing a new scientific and advisory board jam-packed with health care luminaries. Promising to allow low-cost lab testing with just a few drops of blood that can be drawn without needles, Theranos was valued at $9 billion just a few months ago. But as a deal to install testing facilities at Walgreens pharmacies throughout the country is placed on hold, it is experiencing a storm of criticism all but unprecedented for a laboratory.